The global Biliary Tract Cancers (BTCs) Treatment Market is anticipated to reach a market size of US$ 3.2 billion in 2023 and US$ 4.74 billion by exhibiting a CAGR of 4% from 2023 to 2033. From 2018 to 2022, the market for biliary tract cancers (BTCs) treatment experienced a 3% CAGR.
BTCs are a group of rare and aggressive cancers that affect the biliary system, which includes the bile ducts, gallbladder, and liver. These cancers are often diagnosed at an advanced stage, making treatment challenging. However, recent advancements in diagnosis and treatment have improved the survival rates of patients with BTCs.
Get Sample Copy of Latest Reports! https://www.futuremarketinsights.com/reports/sample/rep-gb-16764
According to the American Cancer Society, there were an estimated 12,000 new cases of BTCs in the United States in 2020. Additionally, the increasing adoption of minimally invasive procedures for the treatment of BTCs is also expected to drive market growth. The high cost of treatment and the lack of awareness among patients and healthcare providers about BTCs are some of the major challenges. However, the report suggests that government initiatives to raise awareness about BTCs and provide funding for research and development are expected to overcome these challenges in the coming years.
Key Takeaways from the Market Study:
- The market for treatments for biliary tract cancers (BTCs) expanded at a CAGR of 3% from 2018 to 2022.
- Between 2023 and 2033, the market for biliary tract cancers (BTCs) treatment is anticipated to expand at a 4% CAGR.
- The market for treating biliary tract cancers (BTCs) is anticipated to reach US$ 4.74 billion by 2033.
- The injectable market share is the greatest, according to the Future Market Insights research.
- In the market for biliary tract cancers (BTCs) treatments, North America is anticipated to hold a 40% market share.
- The East & South Asia market is predicted to increase significantly throughout the forecast period, with a share of 20% during the forecast period.
Reach Out To Our Analyst And Get All Your Queries Answered! https://www.futuremarketinsights.com/ask-question/rep-gb-16764
“A series of international level collaborations involving healthcare stakeholders across various institutional settings are fueling further clinical trials and research studies dedicated to discovering Biliary Tract Cancers (BTCs) Treatment.” says an FMI analyst
Market Competition:
Key players in the market include companies such as Incyte Corporation, Loxo Oncology, Bayer, Roche, Genentech, Agios Pharmaceuticals, Servier Pharmaceuticals, Merck Sharp & Dohme, AstraZeneca, Taiho Oncology, Delcath Systems, Eisai, TransThera Sciences (Nanjing), Basilea Pharmaceutica, Zymeworks, and BeiGene, along with healthcare providers and technology companies among other global players.
- In September 2022, Durvalumab (Imfinzi, AstraZeneca UK Limited) was granted approval by the Food and Drug Administration on September 2, 2022 for treating adult patients with locally advanced or metastatic biliary tract cancer (BTC) in combination with gemcitabine and cisplatin. In the TOPAZ-1 (NCT03875235) trial, which was a randomized, double-blind, placebo-controlled, multiregional study, the efficacy of the treatment was evaluated. The trial enrolled 685 patients who had histologically confirmed locally advanced unresectable or metastatic BTC and who had not previously undergone systemic therapy for advanced disease.
The demographics of the trial showed that 56% were Asian, 37% were White, 2% were Black, and 4% were of other races, while 7% were Hispanic or Latino. In terms of gender, 50% were male and 50% were female, with a median age of 64 years (ranging from 20-85). 47% of the participants were 65 years or older. In the trial, 56% of patients had intrahepatic cholangiocarcinoma, 25% had gallbladder cancer, and 19% had extrahepatic cholangiocarcinoma.
More Insights Available
FMI, in its new offering, presents an unbiased analysis of the global Biliary Tract Cancers (BTCs) Treatment market, presenting historical analysis from 2018 to 2022 and forecast statistics for the period of 2023 to 2033.
The study reveals essential insights on the basis of Product Type, Molecule Type, Route of Administration, Drug Class & Region.
Elevate Your Brand: Explore the Insights from Our Customization Report! https://www.futuremarketinsights.com/customization-available/rep-gb-16764
Key Segments Profiled in the Biliary Tract Cancers (BTCs) Treatment Industry Survey
Drug Class:
- Durvalumab
- Zanidatamab
- Ramucirumab
Route of Administration:
- Inhalation
- Intravenous
- Intranasal
- Subcutaneous
- Oral
- Parenteral
Molecule type:
- Antibody
- Antisense oligonucleotides
- Immunotherapy
- Monoclonal antibody
- Peptides
- Protein
- Small molecule
- Stem Cell
Product Type:
- Mono
- Combination
- Mono/Combination
Region:
- North America
- Latin America
- Europe
- East Asia
- South Asia
- Oceania
- Middle East & Africa
About Future Market Insights (FMI)
Future Market Insights, Inc. (ESOMAR certified, recipient of the Stevie Award, and a member of the Greater New York Chamber of Commerce) offers profound insights into the driving factors that are boosting demand in the market. FMI stands as the leading global provider of market intelligence, advisory services, consulting, and events for the Packaging, Food and Beverage, Consumer Technology, Healthcare, Industrial, and Chemicals markets. With a vast team of over 5000 analysts worldwide, FMI provides global, regional, and local expertise on diverse domains and industry trends across more than 110 countries.
Contact Us:
Future Market Insights Inc.
Christiana Corporate, 200 Continental Drive,
Suite 401, Newark, Delaware – 19713, USA
T: +1-845-579-5705
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com
LinkedIn| Twitter| Blogs | YouTube